Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | ALPL | P05186 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5022767 | 0.85 | TSHR (0.58) | TSHRPOLBNPC1RAB9ALMNA | |
| SCHEMBL18003909 | 0.82 | SMN1; SMN2 (0.61) | TSHRPOLBNPC1RAB9ALMNA | |
| SCHEMBL14132421 | 0.80 | LMNA (0.70) | POLBLMNASMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL18003584 | 0.78 | SMN1; SMN2 (0.57) | TSHRPOLBNPC1RAB9ALMNA | |
| SCHEMBL2175058 | 0.77 | SMN1; SMN2 (0.47) | TSHRPOLBNPC1RAB9ALMNA | |
| SCHEMBL2175062 | 0.77 | SMN1; SMN2 (0.47) | TSHRPOLBNPC1RAB9ALMNA | |
| SCHEMBL6449685 | 0.77 | FAAH (0.66) | POLBNPC1RAB9ALMNAALDH1A1 | |
| SCHEMBL18361784 | 0.76 | SMN1; SMN2 (0.46) | TSHRPOLBNPC1RAB9ALMNA | |
| SCHEMBL8122806 | 0.75 | SMN1; SMN2 (0.49) | TSHRPOLBLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL1349111 | 0.75 | SMN1; SMN2 (0.52) | TSHRPOLBNPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346872-B1 | AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2015-11-25 | — | — | EP | disclosed |
| EP-2346872-B1 | AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2015-11-25 | — | — | EP | disclosed |
| US-8754211-B2 | Azolotriazinone melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754211-B2 | Azolotriazinone melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754211-B2 | Azolotriazinone melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-17 | — | — | US | disclosed |
| US-20140031337-A1 | AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031337-A1 | AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031337-A1 | AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-30 | — | — | US | disclosed |
| US-8580959-B2 | Azolotriazinone melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580959-B2 | Azolotriazinone melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580959-B2 | Azolotriazinone melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-12 | — | — | US | disclosed |
| US-20110218185-A1 | AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | SYNGENE INTERNATIONAL LIMITED (IN) | 2011-09-08 | — | — | US | disclosed |
| US-20110218185-A1 | AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | SYNGENE INTERNATIONAL LIMITED (IN) | 2011-09-08 | — | — | US | disclosed |
| US-20110218185-A1 | AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | SYNGENE INTERNATIONAL LIMITED (IN) | 2011-09-08 | — | — | US | disclosed |
| EP-2346872-A1 | AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010042682-A1 | AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010042682-A1 | AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031337-A1 | AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | MCHR1, MCHR2, MC1R | TSHR 36/4885POLB 4638/4885NPC1 671/4885 |
| US-20110218185-A1 | AZOLOTRIAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | MCHR1, MCHR2, MC1R | TSHR 36/4885POLB 4638/4885NPC1 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.